[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis]

A Masson-Lecomte; D Vordos; A de la Taille; Y Neuzillet; F Radvanyi; Y Allory

doi:10.1016/j.purol.2012.12.003

[Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis]

Prog Urol. 2013 Feb;23(2):96-8. doi: 10.1016/j.purol.2012.12.003. Epub 2013 Jan 5.

[Article in French]

Authors

A Masson-Lecomte¹, D Vordos, A de la Taille, Y Neuzillet, F Radvanyi, Y Allory

Affiliation

¹ Inserm U955 équipe 7, service d'urologie, université Paris-Est Créteil, CHU Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94000 Créteil, France. [email protected]

PMID: 23352301
DOI: 10.1016/j.purol.2012.12.003

Abstract

FGFR3 mutation leads to a constitutive activation of the receptor 3 to Fibroblast Growth Factor. This mutation is early in urothelial carcinogenesis and is strongly associated to low grade papillary tumors. Multiple regional epigenetic silencing (MRES) phenotype corresponds to the transcriptional inactivation of chromosomal regions in muscle invasive bladder cancer, and is strongly associated to the molecular signature of carcinoma in situ. These alterations could be targeted by new specific therapies.

Publication types

English Abstract

MeSH terms

Biomarkers / blood
Carcinoma / blood
Carcinoma / genetics*
Carcinoma / metabolism
Carcinoma / pathology
Carcinoma in Situ / genetics
Cell Transformation, Neoplastic / genetics
Epigenesis, Genetic*
Gene Silencing*
Humans
Mutation*
Phenotype
Receptor, Fibroblast Growth Factor, Type 3 / genetics*
Urinary Bladder Neoplasms / blood
Urinary Bladder Neoplasms / genetics*
Urinary Bladder Neoplasms / metabolism
Urinary Bladder Neoplasms / pathology
Urothelium / metabolism
Urothelium / pathology

Substances

Biomarkers
FGFR3 protein, human
Receptor, Fibroblast Growth Factor, Type 3